Natalizumab and progressive multifocal leucoencephalopathy

Current data suggest that as many as 1 in 1000 treated individuals may develop progressive multifocal leucoencephalopathy (PML) in concert with the use of natalizumab. Natalizumab was withdrawn in early 2005. The present paper provides a comprehensive description of PML and reviews the role of natal...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the rheumatic diseases 2006-11, Vol.65 (suppl 3), p.iii48-iii53
1. Verfasser:	Berger, J R
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome AIDS AIDS-Related Opportunistic Infections - chemically induced AIDS-Related Opportunistic Infections - therapy Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Biological and medical sciences Bone marrow central nervous system cerebrospinal fluid CNS CSF demyelination Disease HAART highly active antiretroviral therapy HIV Human immunodeficiency virus Humans Immune system Immunomodulators JC virus JCV Leukoencephalopathy, Progressive Multifocal - chemically induced Leukoencephalopathy, Progressive Multifocal - diagnosis Leukoencephalopathy, Progressive Multifocal - therapy Lymphocytes Medical imaging Medical sciences monoclonal antibodies Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Natalizumab Nervous system Opportunistic Infections - chemically induced Opportunistic Infections - diagnosis Opportunistic Infections - therapy Patients Pharmacology. Drug treatments PML Polymerase chain reaction Prognosis progressive multifocal leucoencephalopathy Spleen Tomography Viral infections Visual impairment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Current data suggest that as many as 1 in 1000 treated individuals may develop progressive multifocal leucoencephalopathy (PML) in concert with the use of natalizumab. Natalizumab was withdrawn in early 2005. The present paper provides a comprehensive description of PML and reviews the role of natalizumab in the pathogenesis of PML. It is likely that use of drugs which cause specific perturbations of the immune system will be accompanied by similar rare infections. Thus researchers should be on the alert when using such agents in clinical trials.
ISSN:	0003-4967 1468-2060
DOI:	10.1136/ard.2006.058404